Spinal Cord Stimulation in Chemotherapy Induced Neuropathy
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Neurology |
| Therapuetic Areas: | Neurology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/9/2018 |
| Start Date: | December 3, 2018 |
| End Date: | October 2021 |
| Contact: | Joshua Smith, MD |
| Email: | PSmith9@ghs.org |
| Phone: | (864) 522-5030 |
Effectiveness of Spinal Cord Stimulation as Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Pilot Trial
This is an observational based pilot study evaluating the use of spinal cord stimulators for
the treatment of chemotherapy induced peripheral neuropathy will lead to an increase in
quality of life and decrease in pain.
the treatment of chemotherapy induced peripheral neuropathy will lead to an increase in
quality of life and decrease in pain.
Cancer treatment, for many patients, results in painful side effects. As evidence mounts
demonstrating the risks associated with long term opioid therapy, non-opioid modalities need
to be developed. Spinal cord stimulators are implanted devices that modulate the pain
signaling system in the spinal cord. This research hopes to determine if the use of a spinal
cord stimulator in patients with chemotherapy induced peripheral neuropathy will lead to an
increase in quality of life and decrease in pain.The primary endpoints will be the number of
patients who undergo permanent implantation. The endpoints will measure pain with the Brief
Pain Inventory Short Form visual analog scale. The sleep quality will be measured using the
Pittsburgh Sleep Quality Assessment.
demonstrating the risks associated with long term opioid therapy, non-opioid modalities need
to be developed. Spinal cord stimulators are implanted devices that modulate the pain
signaling system in the spinal cord. This research hopes to determine if the use of a spinal
cord stimulator in patients with chemotherapy induced peripheral neuropathy will lead to an
increase in quality of life and decrease in pain.The primary endpoints will be the number of
patients who undergo permanent implantation. The endpoints will measure pain with the Brief
Pain Inventory Short Form visual analog scale. The sleep quality will be measured using the
Pittsburgh Sleep Quality Assessment.
Inclusion Criteria:
• The patient has persistent, severe peripheral neuropathy secondary to chemotherapy
Exclusion Criteria:
• Refusal to undergo a spinal cord stimulator procedure
We found this trial at
1
site
175 Patewood Drive
Greenville, South Carolina 29615
Greenville, South Carolina 29615
Principal Investigator: Joshua Smith, MD
Click here to add this to my saved trials
